Peter Dolan
Peter Dolan
Peter R. Dolanis an American business executive. In 2009, he became Chairman and CEO of Gemin X Pharmaceuticals after joining board in July 2008, he was formerly the chief executive officer of Bristol-Myers Squibb before being discharged from that company in September 2006 as a result of a federal investigation into questions concerning the patent of drug Plavix...
based board bringing meeting next present raising together town
I've put together a proposal, based on negotiations with Metro-North, that I'll present at our next Town Board meeting for raising our fees and bringing them in line.
businesses growing impressive key record track
Lamberto is an outstanding leader, with an impressive track record at Bristol-Myers Squibb of growing key franchises and businesses around the world,
addressing against agreement aids approach builds commitment committing ensure fight global including medicines pandemic patents prevent prices profit providing taken treatment
This agreement builds on Bristol-Myers' long-standing commitment to the global fight against AIDS. In Sub-Saharan Africa, where the HIV/AIDS pandemic has been especially devastating, we've taken a broad-based approach to addressing the AIDS crisis, including providing our AIDS medicines at no profit prices and committing to ensure our patents do not prevent inexpensive treatment in the region.
career leadership
Over his 24-year career with Bristol-Myers Squibb, Don has demonstrated extraordinary leadership on many different fronts,